pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›IMDELLTRA
drug · antibody
save

IMDELLTRA

updated 6mo ago
by $AMGN AMGEN INC🔗 ChEMBL
community read0 votes

🐶 often sniffed alongside

top 3
  • tagApproval8 co-mentions · 2 sources
  • drugtarlatamab8 co-mentions · 2 sources
  • company$AMGNAMGEN INC4 co-mentions · 2 sources

Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 3 investigational indications.

targets

Delta-like protein 3T cell surface glycoprotein CD3

all catalysts(0)

nothing on the calendar yet

News(10)

  • Amgen starts MariTide autoinjector study as pivotal readouts approach
    With the first Phase 3 data expected for Amgen’s MariTide next year, analysts are looking for evidence that the GLP-1 candidate is tolerable. Meanwhile, the company has begun testing an autoinjecto…
    biospace · 15d ago
  • Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
    Molecular Partners plans to lay off up to 44% of its staff as it focuses its declining cash reserves on a radiotherapeutic pipeline led by an early-phase small cell lung cancer drug candidate.
    fiercebiotech · 20d ago
  • A possible treatment for brain-eating amoebas, found in the sea
    Brain-eating amoebas are hard to treat and nearly always fatal. But researchers have isolated a compound that could help stop the disease.
    stat · 23d ago
  • ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
    At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share sell-off on Wall Street, while a lung drug received a standing ovation.
    biopharma_dive · 24d ago
  • ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
    When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…
    biospace · 24d ago
  • STAT+: The ESMO presentation everyone’s been waiting for
    Moderna and Merck's 'presidential' presentation, and other news from Day 2 of the European Society for Medical Oncology meeting in Madrid.
    stat · 26d ago
  • #ESMO26: Amgen's Imdelltra regimen more than halves risk of death in Phase 3 lung cancer trial
    MADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small cell lung cancer patie…
    endpoints · 26d ago
  • Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
    Another day, another Roche deal. The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell engager (TCE) that could go head-to-head with…
    endpoints · 27d ago
  • Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
    Roche is paying Zymeworks $55 million upfront for ZW209, bagging global rights to a trispecific designed to improve on the rate and depth of responses achieved by Amgen’s Imdelltra.
    fiercebiotech · 27d ago
  • ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
    Boehringer Ingelheim has shared data on its DLL3xCD3 T-cell engager, providing pointers to the prospects of a would-be rival to Amgen’s Imdelltra that entered phase 3 this year.
    fiercebiotech · 28d ago
view all news mentions →
brand
IMDELLTRA
trade names
Imdelltra
generic
TARLATAMAB-DLLE
MOA
12.1 Mechanism of Action Tarlatamab-dlle is a bispecific T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. Tarlatamab-dlle had anti-tumor activity in mouse models of SCLC.
indication
1 INDICATIONS AND USAGE IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. IMDELLTRA is a bispecific delta-like ligand 3 (DLL3)-directed CD3 T- cell engager indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum - based chemotherapy. ( 1 )
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?